Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 14/20 | 0.42 |
| ▸ | GRK5 | P34947 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 3/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16554797 | 0.85 | FYN (0.42) | FYNGRK5TGFBR1METPDK2 | |
| SCHEMBL16554998 | 0.81 | FYN (0.44) | FYNGRK5TGFBR1MET | |
| SCHEMBL3411895 | 0.79 | FYN (0.64) | FYNGRK5MET | |
| SCHEMBL16554646 | 0.76 | DYRK1A (0.50) | FYNMETPDK2 | |
| SCHEMBL16554590 | 0.74 | FYN (0.46) | FYNGRK5 | |
| SCHEMBL29533296 | 0.72 | CCR1 (0.44) | PDK2 | |
| SCHEMBL21644070 | 0.69 | FYN (0.61) | FYN | |
| SCHEMBL22530216 | 0.69 | KCNH2 (0.54) | PDK2 | |
| SCHEMBL16562599 | 0.68 | FYN (0.41) | FYNGRK5TGFBR1 | |
| SCHEMBL23630967 | 0.68 | KCNJ5 (0.48) | PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3041473-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2016-07-13 | — | — | EP | disclosed |
| US-20150183791-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2015-07-02 | — | — | US | disclosed |
| US-20150183791-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2015-07-02 | — | — | US | disclosed |
| US-20150183791-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2015-07-02 | — | — | US | disclosed |
| WO-2015035167-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| WO-2015035167-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183791-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | IRAK2, IRAK1, GRB2 | FYN 712/4885GRK5 328/4885TGFBR1 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.